Document text
Principal Investigator: HENRY PAUL PARKMAN
Organization: TEMPLE UNIV OF THE COMMONWEALTH
Fiscal Year: 2022
Award: $1
Funding agency: National Institute of Diabetes and Digestive and Kidney Diseases
PROJECT SUMMARY
Patients with gastroparesis often suffer with chronic symptoms that are not adequately treated due to both a
lack of understanding of the underlying pathophysiology of gastroparesis and lack of effective treatments.
Participation of Temple University as a clinical center in the NIDDK Gastroparesis Clinical Research
Consortium (GpCRC) and Temple's proposed studies will help achieve the broad, long term objectives of
improving the understanding and treatment of patients with gastroparesis. The PI and Temple University are
well qualified to continue to be one of the clinical centers in the GpCRC. Temple University has extensive
clinical expertise in gastroparesis and has been active in study development, enrolling patients into studies,
manuscript publication, and obtaining funding for ancillary studies. The aims for Temple's renewal for the
GpCRC are threefold. First, to continue enrollment and follow-up of patients in current GpCRC studies: GpR3,
BESST, PBG, PSAG. We will maintain the Gastroparesis Registry 3 (GpR3) to enroll 400 patients with follow-
up on patients for 1 to 4 years. GpR3 was recently enhanced to study the effects of SARS-CoV-2 in patients
with gastroparesis. We continue to enroll in the clinical trial Buspirone for Early Satiety and Symptoms of
Gastroparesis (BESST). Our Pathological Basis of Gastroparesis (PBG) is studying immune cell profiles in
gastroparesis. We will start our study on pyloric pathophysiology: Pyloric Sphincter Abnormalities in Patients
with Gastroparesis Symptoms (PSAGS). Second, to better understand the clinical manifestations and
pathophysiology of patients with symptoms of gastroparesis, we will start a new registry, Gastroparesis
Registry 4 for enrollment of 400 new patients. This application includes suggestions for five areas of study: 1)
evaluating for autoimmune gastroparesis; 2) understanding meal eating characteristics and ARFID-like
symptoms in patients with gastroparesis; 3) assess for hypocortisolism which can occur in gastroparesis
patients and add to the symptom severity; 4) assessing for vagal and peripheral neuropathy as
pathophysiologic comorbidities in gastroparesis; and 5) further enhancement of gastric emptying scintigraphy
(GES) assessing antral synchronicity and antropyloroduodenal coordination. Third, to conduct a new
multicenter study investigating the pathophysiology, diagnosis, and treatment of gastroparesis. Our application
proposes a new study, Relating Gastric Pathophysiology using GES with DACS to Treatment Outcome, aimed
at understanding the pathophysiologic basis of gastroparesis and its relationship to symptoms. The goal is to
better target specific treatment based on pathophysiology and symptoms. Temple's participation and proposed
studies will help achieve the goal of the NIDDK GpCRC to advance our understanding and treatment of
gastroparesis.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Active Follow-up><Adrenal Gland Insufficiency><Adrenal Insufficiency><Adrenal gland hypofunction><Ancillary Study><Antibodies><Antral><Area><Autoimmune><Autoimmune Diseases><Biopsy><Biopsy Sample><Biopsy Specimen><Blood Serum><Buspirone><COVID-19 virus><COVID19 virus><Causality><Cell Body><Cells><Characteristics><Chronic><Clinic><Clinical><Clinical Research><Clinical Study><Clinical Trials><CoV-2><CoV2><Development><Diagnosis><Disease><Disorder><Distress><Dysfunction><Dyspepsia><Eating><Endocrine><Enrollment><Etiology><Evaluation><Food Intake><Functional disorder><Funding><Future><Gamma Camera Imaging><Gastric Emptying><Gastric Stasis><Gastroparesis><Goals><Grant><Histologic><Histologically><Human><Hypoadrenalism><Immune><Immunes><Indigestion><Intake><Investigation><Manuscripts><Modern Man><Multi-center studies><Multicenter Studies><Muscle><Muscle Tissue><NIDDK><NIH><National Institute of Diabetes and Digestive and Kidney Diseases><National Institutes of Health><PNS Diseases><Pathologic><Pathology><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Peripheral Nerve Diseases><Peripheral Nervous System Diseases><Peripheral Nervous System Disorders><Peripheral Neuropathy><Physiologic><Physiological><Physiopathology><Publications><Pyloric Sphincters><Pyloric sphincter structure><Questionnaires><Radioisotope Scanning><Radionuclide Imaging><Registries><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Scientific Publication><Scintigraphy><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Severities><Stomach><Suggestion><Symptoms><Syndrome><Techniques><Testing><Thick><Thickness><Tissue Banks><Tissue Collection><Tissue Sample><Tissue repository><Treatment outcome><United States National Institutes of Health><Universities><Wuhan coronavirus><active followup><autoimmune condition><autoimmune disorder><base><causation><chronic symptom><clinical center><co-morbid><co-morbidity><comorbidity><coronavirus disease 2019 virus><coronavirus disease-19 virus><delayed gastric emptying><developmental><diabetic><diabetic gastroparesis><disease causation><early fullness><early satiation><early satiety><effective therapy><effective treatment><enroll><feeding><follow up><follow-up><followed up><followup><gastric><gastrointestinal symptom><hCoV19><improved><improved outcome><interest><minority patient><multidisciplinary><muscular><nCoV2><pathophysiology><patient population><patients from minority><patients of minority><persistent symptom><radionuclide imaging/scanning><radionuclide scanning><recruit><response to therapy><response to treatment><satiated early><stomach emptying><symptom treatment><symptomatic treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic response><therapy response><treat symptom><treatment response><treatment strategy><urban area><urban location><urban region>